China’s VivaVision Biotech Inc. announced the first patient enrollment in a Phase II clinical study of its dual-targeting drug VVN539 for open-angle glaucoma in the US. The trial marks progress in the company’s pipeline targeting ophthalmic disorders.
Study Details
The randomized, double-blind, vehicle-controlled Phase II study will assess VVN539’s safety and efficacy in reducing intraocular pressure (IOP) in open-angle glaucoma or ocular hypertension. The trial will enroll 60 subjects across 7 US centers, with participants receiving 3 weeks of treatment and IOP assessments at days 7, 14, and 21.
Drug Profile
VVN539 acts directly on the eye’s trabecular meshwork to enhance aqueous humor outflow, lowering IOP. Preclinical data showed significant IOP reduction, with efficacy expected to match prostaglandins. The drug’s mechanism allows potential combination with other therapies.
Company Background
VivaVision focuses on innovative ophthalmology and dermatology drugs. The firm plans a Phase I study for VVN461 in noninfectious uveitis in China, expanding its pipeline in ocular diseases.-Fineline Info & Tech
